- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07607158
Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites (BlueBIOME)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study is an acute, single-arm polyphenol pharmacokinetic study designed to evaluate inter-individual variability in the metabolism of blueberry polyphenols and the role of the gut microbiome in shaping these responses. The study will be conducted at Colorado State University in the Food & Nutrition Clinical Research Laboratory. We will enroll approximately 125 healthy adults (≥18 years of age), with stratified recruitment across a range of ages and body mass index (BMI) values to capture diversity in gut microbiome composition. Participants will provide written informed consent prior to participation and will be compensated for their time.
Eligible participants will be generally healthy adults able to provide informed consent and adhere to study procedures. Key exclusion criteria include pregnancy or breastfeeding; pre-specified chronic diseases; recent antibiotic use; conditions affecting nutrient absorption; anemia; BMI ≤18.5 kg/m²; unwillingness to adhere to study protocols; recent blood draw within 1 week; participation in another research study; and contraindications to study procedures, treatments, or supplies.
The study consists of three main components: a screening visit, an acute test day, and a 24-hour follow-up visit. During the initial screening visit, participants will complete a health and medical history questionnaire, anthropometric assessments, blood pressure measurements, and a fasting blood draw to assess metabolic health and eligibility.
Following screening, participants will complete a short lead-in period prior to the test day, during which they will collect stool samples and a 24-hour urine sample at home and complete three 24-hour dietary recalls. They will also follow a low-polyphenol diet for three days prior to the test visit to minimize background variability in polyphenol exposure.
On the test day, participants will report to the laboratory following an overnight fast. Participants will consume a standardized blueberry beverage containing freeze-dried blueberry powder. Serial blood samples will be collected via an indwelling catheter at baseline and at multiple time points over an 8-hour period (0, 1, 2, 4, 6, and 8 hours) to characterize the pharmacokinetics of circulating blueberry polyphenol metabolites. Additional blood samples will be collected for peripheral blood mononuclear cell (PBMC) isolation at hours 4 and 6. Standardized low-polyphenol meals and snacks will be provided during the visit. Participants will also initiate a 24-hour urine collection and receive a stool collection kit for post-visit sampling.
Participants will return approximately 24 hours after blueberry consumption for a follow-up visit, which includes an additional fasting blood draw and return of urine and stool samples.
Throughout the study, additional data will be collected via validated questionnaires assessing gastrointestinal symptoms, sleep quality, physical activity, diet, and social determinants of health. Biological samples (blood, urine, and stool) will be used to assess polyphenol metabolism, gut microbiome composition and function, and related multi-omic profiles.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Tiffany Weir, PhD
- Telefonnummer: (970) 491-4631
- E-Mail: tiffany.weir@colostate.edu
Studieren Sie die Kontaktsicherung
- Name: Jenny Whittington, MS
- Telefonnummer: (970) 310-6843
- E-Mail: ijwhitt@rams.colostate.edu
Studienorte
-
-
Colorado
-
Fort Collins, Colorado, Vereinigte Staaten, 80523
- Rekrutierung
- Colorado State University; Food and Nutrition Clinical Research Laboratory; Gifford Building Room 216; 502 West Lake Street, Fort Collins, CO 80523
-
Hauptermittler:
- Tiffany Weir, PhD
-
Kontakt:
- Jenny Whittington, MS
- Telefonnummer: 970-310-6843
- E-Mail: ijwhitt@rams.colostate.edu
-
Kontakt:
- Tiffany Weir, PhD
- E-Mail: Tiffany.weir@colostate.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Healthy adults ≥18 years of age
- Able and willing to provide informed consent
- Willing and able to adhere to all study procedures and visit requirements
Exclusion Criteria:
- Age <18 years
- Pregnant or breastfeeding
- Presence of chronic diseases, including but not limited to cardiovascular disease, diabetes, cancer, kidney, liver, gastrointestinal, or pancreatic disease
- Use of medications for chronic diseases that may interfere with study outcomes
- Any condition known to negatively impact nutrient absorption (e.g., inflammatory bowel disease, celiac disease, gastroparesis)
- Anemia (hemoglobin <13.5 g/dL in men or <12.0 g/dL in women)
- Body mass index (BMI) ≤18.5 kg/m²
- Use of antibiotics within the past 2 months
- Recent blood draw within 1 week prior to study participation
- Currently participating in another research study involving a diet or exercise intervention
- Known allergy or contraindication to blueberry products or study procedures
- Unwilling or unable to comply with study requirements
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Single-arm
All participants will receive a single dose of the blueberry intervention to characterize pharmacokinetic profiles of polyphenol metabolites.
|
Participants will consume a single oral dose of a standardized blueberry beverage prepared with 22 g of freeze-dried blueberry powder reconstituted in approximately 480 mL of distilled water.
The beverage will be consumed in its entirety at the start of the test visit following an overnight fast.
This dose is selected to provide a defined quantity of blueberry-derived polyphenols for pharmacokinetic assessment.
No additional interventions or comparator treatments will be administered.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetics - Area under the curve (AUC) of circulating blueberry polyphenol metabolites
Zeitfenster: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
Pharmacokinetics - Area under the curve (AUC) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
|
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
|
Pharmacokinetics - Maximum concentration (Cmax) of circulating blueberry polyphenol metabolites
Zeitfenster: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
Pharmacokinetics - Maximum concentration (Cmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
|
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
|
Pharmacokinetics - Time to maximum concentration (Tmax) of circulating blueberry polyphenol metabolites
Zeitfenster: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
Pharmacokinetics - Time to maximum concentration (Tmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
|
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Urinary excretion of blueberry polyphenol metabolites
Zeitfenster: up to 24 hours post-consumption
|
Urinary concentrations of blueberry-derived polyphenol metabolites will be measured via 24-hour urine collection to assess excretion profiles following a single-dose blueberry intervention.
|
up to 24 hours post-consumption
|
|
Gut microbial taxonomic profiling
Zeitfenster: Baseline
|
16s rRNA gene amplicon sequencing of stool samples will be used for exploratory gut microbial taxonomic profiling.
|
Baseline
|
|
Gut microbial functional potential
Zeitfenster: Baseline
|
Metagenomic shotgun sequencing of stool samples will be used for exploratory profiling of gut microbial functional potential.
|
Baseline
|
|
Gut microbial transcripts
Zeitfenster: Baseline
|
Metatranscriptomics will be used for exploratory profiling of gut microbial transcripts.
|
Baseline
|
|
Polyphenol Metabotype
Zeitfenster: Baseline
|
Machine learning methods will be used to determine participant polyphenol metabotypes from pharmacokinetic profiles.
|
Baseline
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 6959
- 1RM1AT013318-01 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .